Clinical Toxicities of Histone Deacetylase Inhibitors

Por Subramanian, Srividya, Bates, Susan E., Wright, John J., Espinoza-Delgado, Igor, Piekarz, Richard L.
Publicado em 2010

Cardiac Involvement with Lymphoma: A Review of the Literature

Por O'Mahony, Deirdre, Piekarz, Richard L., Bandettini, W. Patricia, Arai, Andrew E., Wilson, Wyndham H., Bates, Susan E.
Publicado em 2008

New Strategies in Peripheral T-cell lymphoma: Understanding Tumor Biology and Developing Novel Therapies

Por Dunleavy, Kieron, Piekarz, Richard L., Zain, Jasmine, Janik, John E., Wilson, Wyndham H., O’Connor, Owen A., Bates, Susan E.
Publicado em 2010

Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report

Por Ritchie, David, Piekarz, Richard L., Blombery, Piers, Karai, Laszlo J., Pittaluga, Stefania, Jaffe, Elaine S., Raffeld, Mark, Janik, John E., Prince, H. Miles, Bates, Susan E.
Publicado em 2009

Safety-modified episomal vectors for human gene therapy

Por Cooper, Mark J., Lippa, Mara, Payne, Jennifer M., Hatzivassiliou, Georgia, Reifenberg, Erica, Fayazi, Behnaz, Perales, Jose C., Morrison, Laura J., Templeton, Dennis, Piekarz, Richard L., Tan, June
Publicado em 1997

Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma

Por Woo, Sukyung, Gardner, Erin R., Chen, Xiaohong, Ockers, Sandra B., Baum, Caitlin E., Sissung, Tristan M., Price, Douglas K., Frye, Robin, Piekarz, Richard L., Bates, Susan E., Figg, William D.
Publicado em 2009

A Phase 2 Study of Alisertib (MLN8237) in Recurrent or Persistent Uterine Leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study 0231D

Por Hyman, David M, Sill, Michael W, Lankes, Heather A, Piekarz, Richard, Shahin, Mark S, Ridgway, Mildred R, Backes, Floor, Tenney, Meaghen E, Mathews, Cara A., Hoffman, James S, Aghajanian, Carol, Hensley, Martee L
Publicado no Gynecol Oncol (2016)

MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor

Por Chakraborty, Arup R., Robey, Robert W., Luchenko, Victoria L., Zhan, Zhirong, Piekarz, Richard L., Gillet, Jean-Pierre, Kossenkov, Andrew V., Wilkerson, Julia, Showe, Louise C., Gottesman, Michael M., Collie, Nathan L., Bates, Susan E.
Publicado em 2013

Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers

Por Amiri-Kordestani, Laleh, Luchenko, Victoria, Peer, Cody J., Ghafourian, Kambiz, Reynolds, James, Draper, Deb, Frye, Robin, Woo, Sue, Venzon, David, Wright, John, Skarulis, Monica, Figg, William D., Fojo, Tito, Bates, Susan E., Piekarz, Richard L.
Publicado em 2013

Laboratory Correlates for a Phase II Trial of Romidepsin in Cutaneous and Peripheral T-Cell Lymphoma

Por Bates, Susan E., Zhan, Zhirong, Steadman, Kenneth, Obrzut, Tomasz, Luchenko, Victoria, Frye, Robin, Robey, Robert W., Turner, Maria, Gardner, Erin R., Figg, William D., Steinberg, Seth M., Ling, Alex, Fojo, Tito, To, Kin Wah, Piekarz, Richard L.
Publicado em 2009

A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist, Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer

Por Kelly, Ronan J., Draper, Deborah, Chen, Clara C., Robey, Robert W., Figg, William D., Piekarz, Richard L., Chen, Xiaohong, Gardner, Erin R., Balis, Frank M., Venkatesan, Aradhana M., Steinberg, Seth M., Fojo, Tito, Bates, Susan E.
Publicado em 2010

A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas

Por Park, Sook Ryun, Speranza, Giovanna, Piekarz, Richard, Wright, John J., Kinders, Robert J., Wang, Lihua, Pfister, Thomas D., Trepel, Jane B., Lee, Min-Jung, Alarcon, Sylvia, Steinberg, Seth M., Collins, Jerry, Doroshow, James H., Kummar, Shivaani
Publicado no Cancer Chemother Pharmacol (2013)

A Phase I Study of DMS612, a Novel Bi-functional Alkylating Agent

Por Appleman, Leonard J., Balasubramaniam, Sanjeeve, Parise, Robert A, Bryla, Christine, Redon, Christophe E., Nakamura, Asako J., Bonner, William M., Wright, John J, Piekarz, Richard, Kohler, David R, Jiang, Yixing, Belani, Chandra P., Eiseman, Julie, Chu, Edward, Beumer, Jan H., Bates, Susan E.
Publicado no Clin Cancer Res (2014)

A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical And Translational Study

Por Thomas, Anish, Rajan, Arun, Szabo, Eva, Tomita, Yusuke, Carter, Corey A., Scepura, Barbara, Lopez-Chavez, Ariel, Lee, Min-Jung, Redon, Christophe E., Frosch, Ari, Peer, Cody J., Chen, Yuanbin, Piekarz, Richard, Steinberg, Seth M., Trepel, Jane B., Figg, William D., Schrump, David S., Giaccone, Giuseppe
Publicado em 2014

Impact of ABCB1 allelic variants on QTc interval prolongation

Por Sissung, Tristan M., Gardner, Erin R., Piekarz, Richard L., Howden, Reuben, Chen, Xaiohong, Woo, Sukyung, Franke, Ryan, Clark, James A., Miller-DeGraff, Laura, Steinberg, Seth M., Venzon, David, Liewehr, David, Kleeberger, Steven R., Bates, Susan E., Price, Douglas K., Rosing, Douglas R., Cabell, Christopher, Sparreboom, Alex, Figg, William D.
Publicado em 2010

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

Por Piekarz, Richard L., Frye, Robin, Prince, H. Miles, Kirschbaum, Mark H., Zain, Jasmine, Allen, Steven L., Jaffe, Elaine S., Ling, Alexander, Turner, Maria, Peer, Cody J., Figg, William D., Steinberg, Seth M., Smith, Sonali, Joske, David, Lewis, Ian, Hutchins, Laura, Craig, Michael, Fojo, A. Tito, Wright, John J., Bates, Susan E.
Publicado em 2011

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

Por Piekarz, Richard L., Frye, Robin, Turner, Maria, Wright, John J., Allen, Steven L., Kirschbaum, Mark H., Zain, Jasmine, Prince, H. Miles, Leonard, John P., Geskin, Larisa J., Reeder, Craig, Joske, David, Figg, William D., Gardner, Erin R., Steinberg, Seth M., Jaffe, Elaine S., Stetler-Stevenson, Maryalice, Lade, Stephen, Fojo, A. Tito, Bates, Susan E.
Publicado em 2009

A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia

Por How, Jonathan, Minden, Mark D., Brian, Leber, Chen, Eric X., Brandwein, Joseph, Schuh, Andre C., Schimmer, Aaron D., Gupta, Vikas, Webster, Sheila, Degelder, Tammy, Haines, Patricia, Stayner, Lee-Anne, McGill, Shauna, Wang, Lisa, Piekarz, Richard, Wong, Tracy, Siu, Lillian L., Espinoza-Delgado, Igor, Holleran, Julianne L., Egorin, Merrill J., Yee, Karen W. L.
Publicado no Leuk Lymphoma (2015)

Romidepsin in Peripheral and Cutaneous T-Cell Lymphoma: Mechanistic Implications from Clinical and Correlative Data

Por Bates, Susan E., Eisch, Robin, Ling, Alex, Rosing, Douglas, Turner, Maria, Pittaluga, Stefania, Prince, H. Miles, Kirschbaum, Mark H., Allen, Steven L., Zain, Jasmine, Geskin, Larisa J., Joske, David, Popplewell, Leslie, Cowen, Edward W., Jaffe, Elaine S., Nichols, Jean, Kennedy, Sally, Steinberg, Seth M., Liewehr, David J., Showe, Louise C., Steakley, Caryn, Wright, John, Fojo, Tito, Litman, Thomas, Piekarz, Richard L.
Publicado no Br J Haematol (2015)